Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder | Zendy

Takashi Yamamura | Zendy; Ingo Kleiter | Zendy; Kazuo Fujihara | Zendy; Jacqueline Palace | Zendy; Benjamin Greenberg | Zendy; Beata ZakrzewskaPniewska | Zendy; Francesco Patti | Zendy; ChingPiao Tsai | Zendy; Albert Saiz | Zendy; Hayato Yamazaki | Zendy; Yuichi Kawata | Zendy; Pádraig Wright | Zendy; de Sèze | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

Author(s) -

Takashi Yamamura,

Ingo Kleiter,

Kazuo Fujihara,

Jacqueline Palace,

Benjamin Greenberg,

Beata ZakrzewskaPniewska,

Francesco Patti,

ChingPiao Tsai,

Albert Saiz,

Hayato Yamazaki,

Yuichi Kawata,

Pádraig Wright,

de Sèze

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1901747

Subject(s) - medicine , neuromyelitis optica , placebo , clinical endpoint , spectrum disorder , hazard ratio , randomized controlled trial , gastroenterology , confidence interval , multiple sclerosis , immunology , pathology , alternative medicine , psychiatry

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with autoantibodies to anti-aquaporin-4 (AQP4-IgG) in approximately two thirds of patients. Interleukin-6 is involved in the pathogenesis of the disorder. Satralizumab is a humanized monoclonal antibody targeting the interleukin-6 receptor. The efficacy of satralizumab added to immunosuppressant treatment in patients with NMOSD is unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research